JEVON JOHNSON: Open Payments
NPI 1154512036 · MODESTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,512 in 50 payments from 10 companies in 2025. Trend: 2023 $8,252 · 2024 $8,245 · 2025 $1,512
Food & beverage: $1,301Education: $211
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 9 | $406 |
| Alkermes, Inc. | 7 | $200 |
| Otsuka America Pharmaceutical, Inc. | 9 | $186 |
| ABBVIE INC. | 7 | $167 |
| Janssen Pharmaceuticals, Inc | 4 | $119 |
| Lundbeck LLC | 2 | $114 |
| Vanda Pharmaceuticals Inc. | 3 | $113 |
| E.R. Squibb & Sons, L.L.C. | 5 | $112 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $82 |
| Luye Pharma (USA) Ltd. | 1 | $14 |
Products named: ARISTADA, VRAYLAR, AUSTEDO XR, REXULTI, INVEGA SUSTENNA, HETLIOZ, COBENFY, ABILIFY ASIMTUFII.
Industry payments across CA — which companies pay providers there.
